OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Thoracic Oncology is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Comment on “MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC”	1003
Why and When Do We Invasively Restage After Neoadjuvant Chemoimmunotherapy?	373
Genotype Versus Phenotype: Defining Predictive Biomarkers of Immunotherapy Response	283
Board of Directors	276
PP01.25 Exploring the Impact of Socioeconomic and Geographic Factors on Immunotherapy Discontinuation and Success in Northern Ontario: A Retrospective, Single-Center Cohort Study	255
Translational Analysis of NSD3 Gene Amplification in Lung Squamous Cell Carcinoma: Clinical and Prognostic Insights From Histopathologic Analysis of Patient Samples	232
Serum microRNAs are Associated with Treatment Response and Disease Progression in Limited Stage Small Cell Lung Cancer	223
FBXO11 Mediates PARP Inhibitor Resistance in Small-Cell Lung Cancer	213
PPD01.03: Real World Data On Lung Cancer Detection In A High-Risk Population In A Colombian Insurance Company	190
PP01.21: Evaluating the Accuracy & Reproducibility of ChatGPT Models in Answering Patient’s Lung Cancer Queries	179
EP.08D.06 Neoadjuvant Chemoimmunotherapy Does Not Increase Postoperative Morbidity of Pneumonectomy in NSCLC Patients: A Multi-Center Psmanalysis	167
P1.08C.05 The Clinicopathological and Prognostic Significance of Skip-N2 Metastases: A Retrospective Multicenter Study	154
P4.11E.02 Efficacy of Pembrolizumab Plus Pemetrexed in Older Patients with Non-squamous NSCLC According to PD-L1 Status from the CJLSG1901 Study	149
EP.06D.02 Plasma-Derived Circulating Tumor DNA in Patients with Advanced EGFR-Positive Exon 20 NSCLC Treated With Osimertinib	145
P2.17B.02 Healthcare Providers' Perceptions of Barriers and Enablers to Adopting New Surveillance Protocols	139
OA16.03 Telisotuzumab Vedotin in Asian Patients with C-Met Protein-Overexpressing Non-Squamous EGFR WT NSCLC: Results from LUMINOSITY	138
EP.12A.10 Multi-Omics Uncovers Signatures Associated with Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer Patients	132
EP.04A.01 Lung Cancer Nurse Consultant-Led Pulmonary Nodule Assessment and Surveillance Clinic: Multidisciplinary Team Evaluation	116
EP.15B.04 High-Fiber Intake Predicts Overall Survival in Lung Cancer Patients - Real-World Analyses	113
EP.12A.08 Furmonertinib as First-Line Therapy for Chinese Patients with EGFR Mutation-positive NSCLC: A Real-World Study	113
MA11.13 Peripheral T-Cell Receptor Repertoire Differentiates a Typical Progression in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy	110
MA01.04 AFT-46: CHIO3: Chemotherapy Combined with Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer	107
P2.11C.01 With Eyes on the Future: Prospective Evaluation of Immune-Related Adverse Events in Patients with Lung Cancer	105
EP.07E.02 Physician Prescribing Preferences for Adjuvant Osimertinib in Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer	102
EP.13D.07 Impact of Antiemetic Steroid Use on Survival in Small Cell Lung Cancer Patients with Immune Checkpoint Inhibitors and Chemotherapy Combination	101

P2.04A.07 Improving IPN Management Through CAD and Virtual Nodule Clinics: A Prospective, Observational Multicenter Study (PINPOINT)	97
P1.01A.01 The INHERIT Study - Investigating Hereditary Risk in Thoracic Cancers (NCT05587439)	94
P3.03I.08 Efficacy of Novel Third-Generation Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations- Anin Vitrostudy	93
EP.03F.05 A Dose-Effect Relationship of a Novel Bronchoscopy Guided Endobronchial Radiofrequency Ablation for Peripheral Lung Tumors	92
MA07.09 Genome-Wide CRISPR Screen Identifies SFRP2 as a Novel Stromal Target to Enhance Abscopal Effect of Radioimmunotherapy	91
EP.11A.05 Use of Immune Checkpoint Inhibitors in Advanced NSCLC Cases with Very Poor ECOG-PS: A Real World Experience	90
MA04.05 An Evolution and Expanding Engagement to Excel in Lung Cancer Screening	90
EP.11A.16 Infusion Timing of ICI Monotherapy in Patients with Advanced NSCLC: A Single Institution-Retrospective Study	89
EP.12A.22 Aumolertinib with Chemotherapy as First-Line Treatment in Patients with EGFR-Mutated Advanced NSCLC: A Real-World Study	87
EP.08F.18 Survival and Incidence Trends of Non-Small Cell Lung Cancer in Elderly Patients (>75 Years): Insights from SEER Database	82
P1.01C.04 Key Stakeholder Priorities on Embedding Smoking Cessation Into Lung Cancer Screening: National Australian Consensus Workshop	81
EP.07F.06 Prospective Study of Breath Hold During SBRT Treatment of the Lung: Analysis Reliability of Surface Guidance Alone for Breath Hold	80
P2.17B.03 Improving Lung Cancer Screening Utilization and Efficiency Through a Patient-Centered Pathway with Virtual Visits	80
MA18.09 Comparing Efficient Lung Cancer Screening Strategies for Black and White Americans	80
EP.04A.16 Cost-Effectiveness of Adaptive Schedules for Lung Cancer Screening: A Modeling Study	79
EP.14C.08 Challenges in Diagnosis and Management of Epithelioid Inflammatory Myofibroblastic Sarcoma - Case Report	76
P3.08E.01 Perioperative Chemoimmunotherapy Rescue Cold HLA-Deficient Tumors Inducing Strong Immune Responses and Long-Term Survival	75
P2.11A.26 Prognostic Utility of Peripheral Myeloid Cells for Clinical Outcomes in Patients with NSCLC Treated with Cemiplimab	75
EP.07A.08 Modified Periareolar Incision for Uniportal Segmentectomy	74
P4.11E.13 Real-World Treatment Patterns, Healthcare Cost and Resource Utilization in First-Line Treatment of Metastatic NSCLC in the US	74
EP.16A.01 Patient Experiences of Biomarker Testing: Insights from a Global Patient Experience Survey	74
OA01.06 A Phase II Study of Perioperative Ivonescimab Alone or Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer	72
EP.12A.39 MET Point Mutations as the Mechanism of Resistance to EGFR-TKI Therapy: A Case Report of MET H1094Y-Mediated Resistance to Osimertinib Overcome by Capmatinib and a Systematic Review.	69
P2.14A.10 Real-World Evidence of Ipilimumab Plus Nivolumab Combination Therapy in Patients with Malignant Pleural Mesothelioma	68
P4.11D.05 EGFR Neoantigen Peptide Vaccine Combined with Tislelizumab and Chemotherapy for Advanced NSCLC Resistant to EGFR-TKI Therapy	67
Rethinking Biomarkers for Combination Chemoimmunotherapy	67
Bidirectional Association Between Cardiovascular Disease and Lung Cancer in a Prospective Cohort Study	66
Lung Cancer in Japan	66
Current and Future Treatment Options in the Management of Stage III NSCLC	66
OA04.06 The Global Landscape of Lung Squamous Cell Carcinoma, Lung Adenocarcinoma, Small Cell Lung Cancer Incidence in 2020	65
Selective Depletion of CCR8+Treg Cells Enhances the Antitumor Immunity of Cytotoxic T Cells in Lung Cancer by Dendritic Cells	63
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion	63
Evaluating Prognostic Factors for Sex Differences in Lung Cancer Survival: Findings From a Large Australian Cohort	63
PP01.172 It's Never Too Late To Quit	61
PP01.119 Real-World Use of Lurbinectedin in Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Updated Analysis	59
PP01.112 Treatment Patterns and Outcomes in Second-Line Advanced NSCLC Treated After Prior Platinum Chemotherapy and Immunotherapy Combination Therapy: A Real-World Study	59
Iruplinalkib (WX-0593), the Seventh ALK Tyrosine Kinase Inhibitor Approved in People's Republic of China With More to Come	57
357P: Association of TROP2 quantitative continuous scoring (QCS) normalised membrane ratio (NMR) with efficacy in Chinese patients (pts) with advanced/metastatic non-small cell lung cancer (a/mNSCLC)	56
PP01.26 Proprietary vs Open-Source Radiomic Platform for Lung Cancer Diagnosis	56
253P: Surgical vs non-surgical management of non-small cell lung cancer with brain metastases	55
348P: Pulsed high-dose fractionated radiotherapy combined with enhanced immunotherapy in the treatment of driver gene-negative advanced non-small cell lung cancer: A clinical study	55
422P: Acute pneumonitis in patients receiving thoracic radiotherapy and pre-treated with immune checkpoint inhibitors	55
181P: Evaluating probe-based confocal laser endomicroscopy for lung nodule diagnosis: A comprehensive systematic review and meta-analysis	54
390P: Evaluate the effects of VMAT and IMRT treatment techniques on critical organs with different treatment planning algorithms	54
60P: The FIN-EGFR study: A retrospective observational study to investigate the treatment landscape and outcomes of early and advanced stage patients with EGFR mutated non-small cell lung cancer (NSCL	53
27P: Impact of platinum-based chemotherapy (CT) on acquired resistance (AR) to first-line immunecheckpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC): Individual patient data metanalysis	53
32P: The impact of renal dysfunction and pemetrexed administration dose in KEYNOTE189 on prognosis	53
273P: Effect of lung cancer screening, smoking cessation and cessation smartphone application to health-related quality of life	52
312P: Correlation between immune-related adverse events (irAEs) and survival outcomes in extensive-stage small cell lung cancer (ES-SCLC) patients (pts) treated with chemoimmunotherapy (CT-IO)	52
Quality Performance Indicators for Lung Cancer Screening: Towards the Next Levels?	51

Can Immunotherapy Be Omitted in KRAS G12C-Mutant Lung Cancer by 2025?	51
Predicted Effect of Incidental Pulmonary Nodule Findings on NSCLC Mortality	51
Tobacco News Update - From the IASLC Tobacco Control Committee	50
P1.17.63 Docetaxel and Docetaxel Plus Ramucirumab Demonstrate Similar Real-World Overall Survival: A Contemporary Analysis	50
The 2024 International Association for the Study of Lung Cancer Global Survey on Biomarker Testing	50
P1.17.17 Financial Distress and Concerns Prior to Cancer-Directed Treatment Among Patients With NSCLC	49
EP.13.20 Stereotactic Body Radiotherapy for Limited-Stage Small Cell Lung Cancer: Outcomes From a Single-Institution Retrospective Study	49
EP.17.29 Real-World Effectiveness of Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Without Oncogenic Driver Alteration	49
EP.16.07 Addressing Unmet Needs of the Lung Cancer Community: The Journey to Find and Implement Mind Over Matter	49
MA06.01 Real-World Outcomes of First-Line Immunotherapy Intensification of Patients With Advanced Non-Small Cell Lung Cancer (aNSCLC)	48
EP.06.78 T Lymphocyte Subpopulations as Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Anti-Pd(L)1 Inhibitors	48
P3.12.36 Multicenter Retrospective Study of Selpercatinib Treatment for Advanced or Recurrent RET Fusion-Positive NSCLC in Japan	46
P3.01.17 Age-Sex Disparities in Global Burden and Trend of Lung Cancer and Its Attributable Risk Factors in the United Kingdom From 1990-2021	46
EP.05.03 Analysis of Left Upper Pulmonary Arterial Bronchial Concomitant Consistency Based on Three-Dimensional Reconstruction	46
OA10.02 Bevacizumab Plus Chemotherapy Versus Chemotherapy in Untreated Non-Squamous NSCLC With Brain Metastases: A Randomized, Phase 3 Study	45
PT1.03.02 Single-Cell Profiling of Tumor Lineage Plasticity and the Immune Microenvironment in Transformed Small Cell Lung Cancer	45
P1.17.27 Assessing Sarcopenia in Lung Cancer: Feasibility and Training Considerations of Using Quantitative Imaging Metrics From CT Scans	45
EP.15.07 Living With Lung Cancer-A Qualitative Exploration of Its Psychosocial Impact	44
P2.10.10 Soluble Ceacam5 Resistant ADC for Effective Tumor Targeted Delivery With Clinically Validated Tumor Selective Linker Payload	44
EP.12.38 Firmonertinib(160Mg) Combined With Chemotherapy as First-Line Treatment for Advanced NSCLC Patients With EGFR Mutations and Cns Metastases	44
P2.08.44 Adverse Cardiovascular Events Related to Immune Checkpoint Inhibitors in Staging IB-IIIb Non-Small Cell Lung Cancer: A Real-World Study	44
P3.13.02 The Effectiveness of Anatomical Versus Non-Anatomical Resection for Treatment of Small Cell Lung Carcinoma	43
PT2.16.04 Advancing Lung Cancer Advocacy in Low- and Middle-Income Countries	43
P3.13.26 Sequencing of Stereotactic Body Radiation Therapy and Chemotherapy in Stage I Small Cell Lung Cancer: Practice Patterns and Outcomes	42
P3.12.43 A Phase II Study of Sunvozertinib Combined With Anlotinib in NSCLC Patients Harboring EGFR Ex20Ins and Uncommon EGFR Mutations	42
EP.11.14 Impact of Bone Metastases on the Efficacy of First-Line Immunotherapy in Advanced NSCLC: An Analysis From a Prospective Real-World Study	41
P1.17.49 Real-World Outcomes With IO and Chemo-IO Demonstrate Unmet Need for 1L KRAS G12C-Mutant Advanced NSCLC in the US	41
EP.02.05 Three-Dimensional Visualization of Spreading Tumor Cell Through Air Spaces (STAS) Using High Resolution Phase-Contrast Imaging Method	41
EP.13.08 Early Hospitalization During Chemoradiation for Limited-Stage Small Cell Lung Cancer Is Associated With Inferior Survival	41
EP.01.19 Characteristics of Lung Cancer in Never- and Light-Smokers: A Retrospective Study From Greece	41
P2.02.33 Radiotherapy Induces Ferroptosis and Activates STING Pathway to Reverse Immunotherapy Resistance in LKB1-Mutant Lung Cancer	41
P3.12.09 Efficacy of Tepotinib Against Non-Adenocarcinoma MET Exon 14 Skipping NSCLC: A Subanalysis of the REAL-MET Study	40
EP.12.06 Brilliant First Analysis: A Real-World Study of Characteristics and Safety About Brigatinib as First-Line for Chinese Patients With ALK+ NSCLC	40
P2.15.15 Impact of Palliative Care in Patients With Non-Small Cell Lung Cancer and Brain Metastases: A Retrospective Quality Analysis	40
EP.04.42 Alunghive: Autonomous Registry and Analytics System to Transform Clinical Workflow and Enable Multicenter Lung Cancer Screening Research	40
P3.16.09 A Study of Testing Knowledge Regarding Lung Cancer Screening Among General Population and Caregivers	40
OA01.04 Investigating the Association Between Procedure Duration of Coronary Angiography and Intervention and Postoperative Cancer Risk	39
P2.15.17 Preliminary Results on Feasibility of Virtual Delivery of Exercise Therapy for Mitigation of Lung Cancer Decline	39
P1.11.03 Long-Term Efficacy of Immune Checkpoint Inhibitors in Pulmonary Cancer With Rhabdoid Features: A Single-Center Retrospective Analysis	39
EP.09.05 Efficacy and Prognostic Factors of Radiotherapy in Brain Metastases From Non-Small Cell Lung Cancer Patients:A Retrospective Study	39
P1.11.04 Prediction of Overall Survival in Lung Cancer Patients With Different Organ Metastases: A SEER Population-Based Cohort Study	38
Preoperative Biopsy Diagnosis in Patients With Pulmonary Carcinoids: A Biomarker Panel Will Be Crucial to Hit a Bull’s Eye	38
50P Patient-reported outcomes in non-small cell lung cancer patients receiving immunotherapy monotherapy: Analysis from enhanced, EHR-facilitated cancer symptom control (E2C2) pragmatic clinical trial	38
EP08.02-027 T790M Detection Rate After First-Line Treatment with Bevacizumab Plus 1st or 2nd Generation EGFR-TKI in Advanced NSCLC	37
EP04.01-001 Prevalence And Outcomes of EGFR Exon 20 Insertion Mutation In NSCLC: Princess Margaret Cancer Center Experience	37
OA11.06 Sequencing of ctDNA Revealed Radiotherapeutic Efficacy and Prognosis in Non-small Cell Lung Cancer Patients with Brain Metastasis	37
115P Salvage surgery in patients with locally advanced or metastatic non-small cell lung cancer	37
PP.04 EGFR Structure-Based Classification and Presence of Commutations in Peruvian Patients With Advanced Lung Cancer	37
Response to Letter to the Editor From Binghao Zhao et al	36
Table of Contents	36
In This Issue/Research Watch/News in Brief	35
P1.25-15 Trends and Disparities in Curative-Intent Treatment for Early-Stage Non-Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT	34
EP01.01-09 Radiation Exposure in Intraoperative Navigation for Peripheral Small Pulmonary Nodule	34
P1.22-02 Whole Genome Sequencing Analysis of ALK-rearranged Non-small Cell Lung Cancer	34
EP11.03-004 Identification of Filigree Pattern Increases Diagnostic Accuracy of Micropapillary Pattern on Frozen Section for Lung Adenocarcinoma	34
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC	33
EP12.01-44 A Lung Adenocarcinoma Patient with Co-mutations of MET Exon 14 Skipping and EGFR exon21 L858R responded to Aumolertinib	33
P2.13-02 Molecular Subtyping of Small Cell Lung Carcinoma: An Attempt at Unravelling Its Biological Heterogeneity	32
EP17.04-01 The Impact of the Emergency Presentation of Patients Diagnosed with Lung Cancer on Treatment Outcomes in Wales	32
P1.21-11 Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%	32
P1.26-06 Harmonized Maximum Standardized Uptake Value as an Indicator for Sublobar Resection: A Multicenter Retrospective Study	32
Lung Cancer in Nepal	31
EP07.04-17 Study on the Regulatory Mechanism of OM-85 BV on the Immune Microenvironment of Clinical Early-stage Lung Adenocarcinoma	31
Editorial Board	30
OA08.06 Implementation of a Nurse-led Geriatric Oncology Assessment Model in the Lung Cancer Care Pathway	30
Establishment of Tumor Immune Microenvironment Classification Model to Select Patients Sensitive to Immunotherapy	30
EP07.02-15 Longitudinal ctDNA Testing in Resected, Early Stage Non-small Cell Lung Cancers	30
EP14.03-12 Anastomosing Hemangioma of Mediastinum and Pleura Mimicking Chest Malignancy	30
P2.20-05 The Impact of Preoperative Immunotherapy On Peri-Operative Outcomes After Thymectomy for Thymic Epithelial Tumors	29
EP11.03-31 Quantification of Interstitial Lung Abnormality Using Deep Learning in Cancer Patients Who Underwent Immune Checkpoint Inhibitors	29
OA15.05 Lung Immune Prognostic Index Predicts Outcomes from Upfront Chemotherapy + Immunotherapy +/- Antiangiogenic in Advanced NSCLC	29
73P Qualitative research to evaluate perceptions around biomarker testing and patient-reported outcomes (PROs) for use in studies of non-small cell lung cancer (NSCLC)	29
P1.25-13 Enhanced Assessment Of Recurrence Risk Of Stage I NSCLC By Combined Adenocarcinoma Grading System And Serum Proteomic Testing	29
P1.16-03 Transbronchial Cryobiopsy Using 1.1 mm-Diameter Cryoprobe for the Diagnosis of Early Stage Lung Cancer	29
European Society of Thoracic Surgeons (ESTS)	29
The Causality Between Statin Use and Reduced Mortality of Esophageal Cancer Remains Unproven	29
EP12.01-73 Aumonertinib in EGFR-Mutant NSCLC Patients with Liver Dysfunction after TKI Treatment and NSCLC with Basic Hepatopathy as First-Line Therapy	29
In This Issue/Research Watch/News in Brief	28
EP12.01-62 Osteoblastic Bone Reaction in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Treated with Osimertinib	28
EP04.04-05 Ten-year CTNB Data Indicate Its Usefulness and Safety, Especially Salvage Situation after Bronchoscopy without Diagnosis	28

EP05.01-11 Lung Cancers Diagnosed in a Retrospective Cohort of Lung Nodule Patients in Singapore	28
Meeting Announcements	27
MA03.06 Respiratory Tract Malignancy-associated Mortality Attributable to Particulate Matter in South Asia from the Global Burden of Disease	27
Meeting Announcements	27
P1.26-05 Sublobar Resection is Equivalent to Lobectomy for Stage IA Adenocarcinoma Presenting as Subsolid Nodule	27
MA17.05 Real World Outcomes of Immunotherapy (IO) for Pleural MESOthelioma in Australia - RIOMeso	27
EP05.01-04 A Retrospective Study on the Efficacy and Safety of Flexible Bronchoscopy in Elderly Patients with Suspected Primary Lung Cancer	27
EP11.03-39 Platinum/Taxane versus Docetaxel +/- Ramucirumab for Metastatic Lung Cancers That Progressed on Platinum Doublets and Anti-PD1/PD-L1	26
25P Furmonertinib plus icotinib for first-line treatment of EGFR-mutated non-small cell lung cancer	26
EP11.04-01 Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer	26
63P Inflammatory indexes and treatment response as correlates of pembrolizumab effectiveness in patients with PD-L1≥50%: Data from the real-life practice	26
Board of Directors	26
MA10.05 Model-based Evaluations of the Cost-effectiveness of Interventions for Lung Cancer: A Systematic Review	26
P2.01-05 The Safety and Efficacy of Induction Chemoimmunotherapy Followed by Radiotherapy and Consolidation Immunotherapy in Locally Advanced NSCLC	26
EP03.03-06 The Involvement of Tumor Endothelial Cells in the Regulation of PD-L1 and Tregs in the Immune Microenvironment of Early-stage Lung Adenocarcinoma	26
EP14.03-07 Three Cases of Mediastinal Teratoma Resulting in Thoracic Perforation	25
Editorial Commentary: Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC	25
EP07.04-10 Early-Stage EGFR Mutated NSCLC: Outcomes After Surgical Resection at a Large Academic Medical Center	25
P1.05-01 Research on Specific DNA Methylation Regulatory Mechanism Based on Pan-Cancer Analysis	25
EP13.01-10 Mitotic Counts and Phospho-Histone H3 Index in Grading Pulmonary Neuroendocrine Tumors: Assessment of Interobserver Variability and Utility	24
EP03.02-03 High-Throughput Screening Reveals Ceritinib as a Sensitizer for Cafs-Induced Osimertinib Resistance in Non-small Cell Lung Cancer	24
OA12.03 An Analysis of the Rate of Second Primary Lung Cancer from CALGB (Alliance) 140503 Trial of Lobar versus Sub-Lobar Resection for T1aN0 NSCLC	24
P2.17-02 EFfectiveness and Safety Profile of Lurbinectedin in Second-Line Small Cell Lung Cancer: A Real-World Study	24
Neurocognitive Adverse Events in Patients With ALK or ROS1-Positive, Advanced or Metastatic NSCLC Receiving Lorlatinib	23
P1.25-07 Prevalence of EGFR Mutations in Patients with Resected Stage I-III NSCLC: Results of the Asian Cohort of EARLY-EGFR	23
EP01.01-007 Incorporating cfDNA Detection to CT Scan Assessment in Post-Surgical Lung Cancer Patients	23
EP04.06-04 Impact of a Navigational Program on Lung Cancer Screening at a Community Health Center Serving an Urban Diverse Population	23
WS08.07 Evaluation of a Risk-sharing Agreement for Atezolizumab Treatment in NSCLC Patients: A Strategy to Improve Access in Low Income Countries	23
Meeting Announcements	23
P2.07-08 Checkpoint Inhibitor Pneumonitis Model for NSCLC based onPreexistingLung Ground Glass Opacities: Development and Validation	23
EP08.01-093 ICI in Combination With Chemotherapy or Anti-angiogenic Agents as Second-Line Orbeyondtreatment for Advanced Non-small Cell Lung Cancer	22
EP01.06-002 Impact of Immediate AI Enabled Patient Triage to Chest CT on the Lung Cancer Pathway: LungIMPACT	22
EP08.02-119 RNA Sequencing to Characterize Pathways in EGFR-mutated Non-Small Cell Lung Cancer	22
EP08.01-021 Phase 2 Study Evaluating Inupadenant in Combination with Chemotherapy in Adults with NSCLC who Progressed on Immunotherapy	22
EP05.01-023 Feasibility of Functional Lung Avoidance using Ga-68 4D Ventilation Perfusion PET/CT: The HI-FIVE Trial	22
EP08.02-163 Real-World Case Series on Efficacy and Safety of Amivantamab for EGFR-mutant Non-small Cell Lung Cancer	22
P2.07-01 Deep-Learning Based Prediction of c-MET Status from Digitized H&E-Stained Non-Small Cell Lung Cancer Tissue Samples	22
213P Development of an explainable clinical decision support tool for advanced lung cancer patients	22
EP16.03-018 Molecular Features of Subtypes Classified Based on Predominance and Components in Chinese Patients with Lung Adenocarcinoma	22
EP07.03-001 Comparison of Treatment Outcomes in Neoadjuvant Chemotherapy and Chemo-radiotherapy for Thymoma and Thymic Carcinoma	22
MA04.09 The Incidence and Predictors of Unsuspected Brain Metastases in Patients with Stage IA NSCLC	22
Pitfalls in Molecular Testing and the Added Value of the Cancer Research Biomedical Community	22
218P Implications of the eighth edition of TNM staging system for thymoma, a single-center retrospective study	22
EP07.01-024 Preclinical Investigation of Immune Checkpoint Blockade and Anti-Angiogenic Therapy in Malignant Pleural Mesothelioma	21
EP14.02-006 Subtype-specific Hypersensitivity to Oxidative Phosphorylation Inhibition in Small Cell Lung Cancer	21
EP08.02-041 NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study	21
In Response to Continuation of Lorlatinib Beyond Progressive Disease	21
EP08.01-055 Utilization of Tumor Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer	21
Beyond Personalized to “Tumoralized” Therapy	21
EP01.07-001 Surveillance with FDG PET/CT after Completion of Therapy for NSCLC: A Status Update on Inclusion in the SUPE_R Trial	21
EP01.04-001 A Programmatic Approach to Improve Efficiency in Lung Cancer Screening	21
Editorial Board	20
EP01.02-006 Excuse Me? Patient Perceptions of Lung Cancer Screening Results	20
EP14.05-019 Contemporary Real-World Adverse Events Associated with Small Cell Lung Cancer Diagnosed in a U.S. Population from 2013-2021	20
EP.02A.02 The Stroma Cell Function in the Border Region Between Lung Cancer and Normal Lung	20
EP08.01-079 Long Term Use of Immune Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer (NSCLC) and Abnormal Marrow Pathology: A Case Series	20
EP04.01-012 Sex and Age-Related Guideline-Adherence Disparities in Non-Small-Cell Lung Cancer Treatment Patterns: Real-World Data	20
EP08.02-100 Combination of Bevacizumab and Continuation of EGFR-TKIs in NSCLC Patients beyond Gradual Progression	20
Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer	19
OA10.03 Tarlatamab Sustained Clinical Benefit and Safety in Previously Treated SCLC: DeLLphi-301 Phase 2 Extended Follow-up	19
240P: Real-world toxicity data for the use of ipilimumab plus nivolumab in malignant mesothelioma across 11 UK centres	19
138P: Outcomes by treatment (tx) cycles (cyc) with perioperative nivolumab (NIVO) in patients (pts) with resectable NSCLC from CheckMate 77 T study	19
Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis	19
The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification	19
P2.11A.23 Fecal Microbiota Transplantation Plus Rechallenging Immunotherapy in Patients with Advanced Non Small Cell Lung Cancer: An Exploratory Study	19
235P: A stage III, non-small cell lung cancer (NSCLC) multidisciplinary meeting (MDT) to increase access to concurrent chemo-radiation in a Northern UK cancer centre	19
137MO: Impact of cardiac substructure dose on cardiotoxicity and overall survival (OS) in early-stage non-small cell lung cancer (ES-NSCLC) patients receiving stereotactic ablative body radiotherapy (	19
Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial	19
Lung Cancer in Romania	19
303P: Identifying novel prognostic markers in small cell lung cancer through comprehensive in-silico analysis	19
248TiP: Phase II study of pembrolizumab in combination with cisplatin or carboplatin and pemetrexed as induction chemoimmunotherapy in resectable epithelioid and biphasic pleural mesothelioma (CHIMERA	19
381P: Empowering global oncology: DBS-TARGETenables high-sensitivity mutation detection anywhere	18
Table of Contents	18
215P: Safety and necessity of mediastinal lymph nodes dissection omission following nodal clearance with neoadjuvant immunochemotherapy in cN0/N1 non-small cell lung cancer	18
205P: EGFR-TKI combined with chemotherapy versus EGFR-TKI alone for locally advanced EGFR-mutant NSCLC: A real-world study	18
24P: 5-year real-world outcomes with first-line (1L) pembrolizumab plus (+) chemotherapy in advanced/metastatic NSCLC	18
310P: Final overall survival (OS) of surufatinib plus PD-1/PD-L1 antibodies as maintenance therapy following first line (1L) platinum-based chemotherapy (Chemo) plus PD-1/PD-L1 antibodies in patients	18
Neoadjuvant or Perioperative Chemoimmunotherapy Treatment in Patients with Resectable NSCLC: Still an Open Question. Comments on Marinelli et al. J Thorac Oncol. 2025;20:285–295	18
150P: Pathologic complete response (pCR) and major pathologic response (MPR) as surrogate endpoints of survival in immunotherapy trials for early-stage NSCLC	18
398P: The roles of ‘Quinacrine’ (QC) in cell migration and angiogenesis are pivotal to the metastatic spread of human lung cancer cells cultured in vitro and xenograft mouse models	18
212P: Recurrence in patients with non-small cell lung cancer achieving pathological complete response after neoadjuvant treatment	18
A Response to the Letter to the Editor: “Genome-Wide Analysis Identifies Nuclear Factor 1C as a Novel Transcription Factor and Potential Therapeutic Target in SCLC”	18
Tobacco News Update—From the IASLC Tobacco Control Committee	18
102P: Molecular characteristics and spatially resolved proteomic immune clusters reveal responsiveness of large cell neuroendocrine carcinomas of the lung (LCNEC) towards the Checkmate-9LA treatment p	18
144P: Perioperative immunotherapy treatment in resectable non-small cell lung cancer with KRAS mutation: A real-world study (Peri-R-01)	18
PP01.76 Optimizing Biomarker Models for Biologically-Heterogeneous Cancers: A Nested Model Approach for Lung Cancer	17
Low Dose Computed Tomography for Lung Cancer Screening in Tuberculosis Endemic Countries: A Systematic Review and Meta-Analysis	17
PP01.19: Surgery improves the survival of Thymic Epithelial Tumors (TETs) patients independently of stage and histological subtype: Real-World Characteristics and Outcomes of a Brazilian retrospective	17
Poziotinib for HER2 Exon 20-Mutated NSCLC: Addition or Burden to the Therapeutic Arsenal?	17
PP01.98 Association between pathological upstaging and overall survival among patients who received anatomic sublobar resection versus lobectomy for lung cancer	17
Overcoming Barriers to Lung Cancer Screening: The Incidental Pulmonary Nodule Strategy	17
Erratum	17
Board of Directors	17
PP01.01: The 2024 International Association for the Study of Lung Cancer (IASLC) Global Survey on Biomarker Testing: Results from Latin America	17
Perioperative Safety and Efficacy of Efgartigimod for Thymoma-Associated Myasthenia Gravis: A Prospective, Multicenter, Phase II Clinical Trial	17